Patients receiving immune checkpoint inhibitor treatment have an increased risk for being hospitalized with immune-related adverse events, particularly if they are older or taking combination treatments, researchers report.
Combining low-dose computed tomography with a blood microRNA test can help establish the most appropriate screening frequency among heavy smokers at risk for lung cancer, study data show.
Video-assisted thoracic surgery lobectomy is associated with less pain, fewer in-hospital complications, and shorter hospital stays compared with open lobectomy for early-stage lung cancer, data from the VIOLET study indicate.
AMG 510, a novel KRAS inhibitor, has promising efficacy and tolerability in previously treated patients with locally advanced or metastatic non-small-cell lung cancer carrying a KRAS G12C mutation, according to phase I trial findings.
Survivors of the 20 most common site-specific cancers, including lung and prostate, are at increased risk for cardiovascular disease in the years that follow diagnosis and treatment, show data published in The Lancet.
A phase II trial shows that the intravenous prodrug fosnetupitant in combination with palonosetron reduces chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy.